Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess

Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess

Introduction: Tumor necrosis factor (TNF) inhibitors (adalimumab, infliximab, etanercept, golimumab, and certolizumab pegol) have revolutionized the treatment of severe immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis...

Full description

Bibliographic Details
Main Authors: Mingming Li, Ruxu You, Yuyong Su, Hongbo Zhou, Shiwei Gong
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Pharmacology
Subjects:
adverse drug reaction
TNFα inhibitors
pharmacovigilance
spontaneous reporting
VigiAccess of the WHO
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1169327/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1169327/full

Similar Items